| |
Building value out of biotech innovation
Giantcode Plc, a subsidiary of Giantcode Corporation Pte Ltd, Singapore, is a UK registered biotech company that focuses on developing our pipeline of clinical assets forward with a primary therapeutic focus against a range of cancers, such as prostata cancer, pancreatic cancer, liver and kidney cancer, lung cancer and, notably, gastro-intestinal cancers. These are areas with obvious unmet medicinal needs. According to the World Health Organisation, there are more than 7 million cancer related deaths worldwide, and the number is growing.
Our organisation supports the preclinical and clinical activities within our internal and external collaborative programs. We actively seek to make strategic alliances for our newest inventions at an early stage during the preclinical phase. In this way, we can give investors early return of the investment since our R&D programs are optimised for low-cost operation and at the same time we can accommodate the technology to fit the strategic partners’ needs. Building value for investors and partners is the mantra.
Our R&D approach is based on getting the key scientific personnel into the lab rather than serving as advisors for young and unexperienced scientists. Thus the company is build with a strong combination of experienced financial, pharma-industry and scientific personnel. With proven excellence in all areas we can leverage the return to the investors and partners, and develop effective medicine to the cancer patients in need.
|
|
